CLOSE X

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma
BSE165.90-0.9 (-0.54 %)
PREV CLOSE ( ) 166.80
OPEN PRICE ( ) 164.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 78760
TODAY'S LOW / HIGH ( )162.95 167.20
52 WK LOW / HIGH ( )109.2 257.7
NSE165.90-1.04 (-0.62 %)
PREV CLOSE( ) 166.94
OPEN PRICE ( ) 165.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 165.90 (3926)
VOLUME 784168
TODAY'S LOW / HIGH( ) 162.80 167.28
52 WK LOW / HIGH ( )109.3 258
GO
(Rs.in Million)
Particulars
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Audited / UnAudited
UnAudited
UnAudited
Audited
UnAudited
Net Sales
271.90
149.10
128.60
168.10
Total Expenditure
803.70
886.00
1157.70
1101.70
PBIDT (Excl OI)
-531.80
-736.90
-1029.10
-933.60
Other Income
NA
1.90
0.40
15.60
Operating Profit
-531.80
-735.00
-1028.70
-918.00
Interest
45.40
28.00
11.40
5.60
Exceptional Items
NA
NA
NA
NA
PBDT
-577.20
-763.00
-1040.10
-923.60
Depreciation
29.50
31.40
31.60
31.40
Profit Before Tax
-606.70
-794.40
-1071.70
-955.00
Tax
-9.00
0.70
1.60
4.00
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
-597.70
-795.10
-1073.30
-959.00
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
-597.70
-795.10
-1073.30
-959.00
Minority Interest
NA
NA
NA
NA
Shares of Associates
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
-597.70
-795.10
-1073.30
-959.00
Equity Capital
324.50
324.50
324.50
324.50
Face Value (IN RS)
1.00
1.00
1.00
1.00
Reserves
NA
NA
NA
NA
Calculated EPS
-1.84
-2.45
-3.31
-2.96
Calculated EPS (Annualised)
-7.37
-9.80
-13.23
-11.82
No of Public Share Holdings
111406493.00
111406493.00
111406493.00
111406493.00
% of Public Share Holdings
34.33
34.33
34.33
34.33
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
-195.59
-494.23
-800.23
-555.38
PBIDTM%
-195.59
-492.96
-799.92
-546.10
PBDTM%
-212.28
-511.74
-808.79
-549.43
PBTM%
-223.13
-532.80
-833.36
-568.11
PATM%
-219.82
-533.27
-834.60
-570.49
 
Notes
Notes
Notes
Notes
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors